Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2015

01.08.2015 | Case Report

Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor

verfasst von: Neila Fathallah, Raoudha Slim, Salaheddine Rached, Wissem Hachfi, Amel Letaief, Chaker Ben Salem

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A drug reaction with eosinophilia and systemic symptom (DRESS) is a severe and rare adverse-drug hypersensitivity syndrome. The evolution of DRESS is unpredictable and haematological abnormalities may occur in 50 % of cases. Sulfasalazine (SSZ) is rarely associated with DRESS. Agranulocytosis is a rare but recognized side-effect to SSZ. Both DRESS and agranulocytosis were not reported previously with SSZ.

Case summary

We report a case of SSZ-induced DRESS followed by severe agranulocytosis occurring in a 25-year-old man. The patient’s general condition and laboratory tests gradually improved after the administration of granulocyte colony-stimulating factor (GCSF).

Discussion

In our patient, the co-occurrence of DRESS and agranulocytosis is unlikely to be coincidental. Immunological mechanisms may play an important role in drug associated agranulocytosis in patients presenting DRESS. According to the Naranjo’s algorithm the likelihood that our patient’s DRESS and agranulocytosis occurred as a result of therapy with SSZ is probable. G-CSF was found to be useful in shortening the duration of granulocyte recovery in drug-induced agranulocytosis.

Conclusion

Careful monitoring of neutrophil counts is required on SSZ therapy as well as in the course of DRESS.
Literatur
1.
Zurück zum Zitat Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6–11.PubMedCrossRef Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6–11.PubMedCrossRef
2.
Zurück zum Zitat Teo L, Tan E. Sulphasalazine-induced DRESS. Singap Med J. 2006;47(3):237–9. Teo L, Tan E. Sulphasalazine-induced DRESS. Singap Med J. 2006;47(3):237–9.
3.
Zurück zum Zitat Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRef
4.
Zurück zum Zitat Komatsuda A, Okamoto Y, Hatakeyama T, Wakui H, Sawada K. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol. 2008;27(3):395–7.PubMedCrossRef Komatsuda A, Okamoto Y, Hatakeyama T, Wakui H, Sawada K. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol. 2008;27(3):395–7.PubMedCrossRef
5.
Zurück zum Zitat Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428–34.PubMedCrossRef Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428–34.PubMedCrossRef
6.
Zurück zum Zitat Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy. 1995;15(2):176–81.PubMed Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy. 1995;15(2):176–81.PubMed
8.
Zurück zum Zitat Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am. 2009;29:481–501.CrossRef Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am. 2009;29:481–501.CrossRef
9.
Zurück zum Zitat Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH. Sulfasalazine-induced DRESS syndrome (drug rash with eosinophilia and systemic symptoms). Sao Paulo Med J. 2008;126(4):225–6.PubMedCrossRef Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH. Sulfasalazine-induced DRESS syndrome (drug rash with eosinophilia and systemic symptoms). Sao Paulo Med J. 2008;126(4):225–6.PubMedCrossRef
10.
Zurück zum Zitat Ibáñez L, Sabaté M, Ballarín E, Puig R, Vidal X, Laporte JR. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Saf. 2008;17:224–8.PubMedCrossRef Ibáñez L, Sabaté M, Ballarín E, Puig R, Vidal X, Laporte JR. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Saf. 2008;17:224–8.PubMedCrossRef
Metadaten
Titel
Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor
verfasst von
Neila Fathallah
Raoudha Slim
Salaheddine Rached
Wissem Hachfi
Amel Letaief
Chaker Ben Salem
Publikationsdatum
01.08.2015
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2015
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0107-2

Weitere Artikel der Ausgabe 4/2015

International Journal of Clinical Pharmacy 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.